<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400202</url>
  </required_header>
  <id_info>
    <org_study_id>SCRIC17-PHYEYE-01</org_study_id>
    <nct_id>NCT03400202</nct_id>
  </id_info>
  <brief_title>Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles</brief_title>
  <official_title>Eye Dark Circles: Physiopathologic Aspects and Influence on Quality of Life in Subjects of Various Ethnicities and Fitzpatrick Skin Types Utilizing Non-invasive In Vivo Instrumentation and Validated Questionnaires</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the physiopathologic characteristics of dark circles in participants
      with various ethnicities and Fitzpatrick Skin Types and the impact of the dark circles on the
      quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Actual">November 7, 2018</completion_date>
  <primary_completion_date type="Actual">November 7, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dark Circles Severity Scale Score</measure>
    <time_frame>Day 1</time_frame>
    <description>The investigator will access the participant's lower and upper eyelids using the Dark Circles Severity Scale where 0=None to 9=Severe (very dark circles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Classification Type of Dark Circles Score</measure>
    <time_frame>Day 1</time_frame>
    <description>The investigator will assess the lower eyelids for the following types of dark circles: Pigmented, Vascular and Shadow Effect. Each of these 3 types are graded where 0=none to 3=severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Questionnaire on Dark Circles, Medical History, and Lifestyle Habits</measure>
    <time_frame>Day 1</time_frame>
    <description>The Subject Questionnaire on Dark Circles, Medical History and Lifestyle Habits is a 15-item questionnaire completed by the participant.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">44</enrollment>
  <condition>Periorbital Hyperpigmentation</condition>
  <arm_group>
    <arm_group_label>Group A: Dark Circles None</arm_group_label>
    <description>Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Dark Circles Mild</arm_group_label>
    <description>Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Dark Circles Moderate</arm_group_label>
    <description>Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Dark Circles Severe</arm_group_label>
    <description>Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Skin imaging</intervention_name>
    <description>Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).</description>
    <arm_group_label>Group A: Dark Circles None</arm_group_label>
    <arm_group_label>Group B: Dark Circles Mild</arm_group_label>
    <arm_group_label>Group C: Dark Circles Moderate</arm_group_label>
    <arm_group_label>Group D: Dark Circles Severe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Facial cleanser</intervention_name>
    <description>Facial cleanser prior to procedures.</description>
    <arm_group_label>Group A: Dark Circles None</arm_group_label>
    <arm_group_label>Group B: Dark Circles Mild</arm_group_label>
    <arm_group_label>Group C: Dark Circles Moderate</arm_group_label>
    <arm_group_label>Group D: Dark Circles Severe</arm_group_label>
    <other_name>SkinMedica Facial Cleanser</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants at a Clinical Research Center.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with Fitzpatrick skin type I-VI

          -  Willingness to not wear any eye makeup on the day of the study visit prior to the
             study visit appointment

          -  Willingness to cleanse the face and remove all makeup at least 15 minutes prior to
             each scheduled clinic visit

          -  Willingness to have facial exams, skin instrumentation measurements, and digital
             photos performed on the face.

        Exclusion Criteria:

          -  Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or
             eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring,
             tattoos, or other skin conditions in the test area

          -  Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active
             hepatitis, immune deficiency, or autoimmune

          -  Individuals who have a pre-existing or dormant dermatologic condition (e.g. history of
             severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)

          -  Individuals who have had a blepharoplasty procedure or any other surgery in proximity
             or affecting the test area

          -  Individuals with recent procedures/surgeries (less than 6 months) on the eye bulb

          -  Individuals with permanent makeup around the eye area

          -  Chemical peel, microdermabrasion, microneedling, or dermaplaning in the previous 4
             weeks

          -  Latisse, Revitalash, or other lash enhancement stimulators in the previous 1 month

          -  Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, Avage® or Differin® or other
             similar prescription drugs within the previous 3 months

          -  Cosmetic injections (filler and/or toxins, i.e.Juvederm, Radiesse, Botox, etc.), non-
             ablative laser or fractional laser resurfacing in the previous 12 months

          -  Accutane® or other oral retinoid, Ablative procedures (i.e. laser, chemical) in the
             previous 12 months

          -  Individuals who have any planned surgeries or procedures during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Goberdhan</last_name>
    <role>Study Chair</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SkinMedica Clinical Research and Innovation Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_AGN_7181&amp;studyid=641&amp;filename=20180209%20CT.gov%20PRF%20Update%20Receipt%20SCRIC17-PHYEYE-01.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 21, 2019</last_update_submitted>
  <last_update_submitted_qc>January 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

